BioCentury | Jun 5, 2006
Company News

Stressgen infectious news

...to Nventa Biopharmaceuticals Corp. The company also changed its ticker to NVN, effective June 7. Stressgen Biotechnologies Corp....
BioCentury | May 22, 2006
Product Development

The end of HPV?

...significant impact on the incidence of HPV-related diseases, noted Gregory McKee, president and CEO of Stressgen Biotechnologies Corp....
...an HPV16-L1E7 fusion protein Treat & prevent cervical cancer associated with HPV Ph I/II compl Stressgen...
BioCentury | Apr 24, 2006
Company News

Stressgen management update

Stressgen Biotechnologies Corp. (TSX:SSB), Victoria, B.C. Business: Infectious Hired: Peter Emtage as VP of R&D, formerly VP of R&D and technical operations at Biomira Inc. Departing: Marvin Siegel as EVP of R&D WIR Staff Infectious...
BioCentury | Apr 10, 2006
Company News

Stressgen board of directors update

Stressgen Biotechnologies Corp. (TSX:SSB), Victoria, B.C. Business: Infectious Appointed: Robert Rieder, vice chairman and CEO of Cardiome Pharma Corp.; and Jay Short, a director, as chairman; he replaces R. Ian Lennox, who resigned WIR Staff...
BioCentury | Jan 2, 2006
Finance

Restructuring watch

...in Phase III. Will focus on other pipeline candidates and acquire products and technologies. 10/18/05 Stressgen...
BioCentury | Oct 24, 2005
Company News

Stressgen infectious news

...in cash and an operating loss of C$17.8 million (US$14.5 million) in the first half. Stressgen Biotechnologies Corp....
BioCentury | Oct 17, 2005
Strategy

Infectious vaccine players

...platform to develop vaccines for various infectious diseases $33.2 Siga (SIGA) Smallpox and streptococcus $30.6 Stressgen...
BioCentury | Jul 18, 2005
Company News

Assay Designs, Stressgen BioReagents Corp. deal

...Research tool company Assay acquired Stressgen BioReagents for an undisclosed sum. Stressgen BioReagents was formed in...
...in April by Ampersand Ventures, at which time the company purchased the reagents business of Stressgen Biotechnologies Corp....
...C$8 million (US$6.5 million) (see BioCentury, April 18). Assay Designs Inc. , Ann Arbor, Mich. Stressgen...
BioCentury | Jul 4, 2005
Finance

Restructuring watch

...multiple Phase I and II pain and cancer compounds and a gene expression technology. 4/27/05 Stressgen...
BioCentury | May 9, 2005
Company News

Stressgen, Ampersand Ventures deal

...BioCentury, April 18). Stressgen BioReagents was formed by Ampersand. The sale included 26 SSB employees. Stressgen Biotechnologies Corp....
Items per page:
1 - 10 of 134
BioCentury | Jun 5, 2006
Company News

Stressgen infectious news

...to Nventa Biopharmaceuticals Corp. The company also changed its ticker to NVN, effective June 7. Stressgen Biotechnologies Corp....
BioCentury | May 22, 2006
Product Development

The end of HPV?

...significant impact on the incidence of HPV-related diseases, noted Gregory McKee, president and CEO of Stressgen Biotechnologies Corp....
...an HPV16-L1E7 fusion protein Treat & prevent cervical cancer associated with HPV Ph I/II compl Stressgen...
BioCentury | Apr 24, 2006
Company News

Stressgen management update

Stressgen Biotechnologies Corp. (TSX:SSB), Victoria, B.C. Business: Infectious Hired: Peter Emtage as VP of R&D, formerly VP of R&D and technical operations at Biomira Inc. Departing: Marvin Siegel as EVP of R&D WIR Staff Infectious...
BioCentury | Apr 10, 2006
Company News

Stressgen board of directors update

Stressgen Biotechnologies Corp. (TSX:SSB), Victoria, B.C. Business: Infectious Appointed: Robert Rieder, vice chairman and CEO of Cardiome Pharma Corp.; and Jay Short, a director, as chairman; he replaces R. Ian Lennox, who resigned WIR Staff...
BioCentury | Jan 2, 2006
Finance

Restructuring watch

...in Phase III. Will focus on other pipeline candidates and acquire products and technologies. 10/18/05 Stressgen...
BioCentury | Oct 24, 2005
Company News

Stressgen infectious news

...in cash and an operating loss of C$17.8 million (US$14.5 million) in the first half. Stressgen Biotechnologies Corp....
BioCentury | Oct 17, 2005
Strategy

Infectious vaccine players

...platform to develop vaccines for various infectious diseases $33.2 Siga (SIGA) Smallpox and streptococcus $30.6 Stressgen...
BioCentury | Jul 18, 2005
Company News

Assay Designs, Stressgen BioReagents Corp. deal

...Research tool company Assay acquired Stressgen BioReagents for an undisclosed sum. Stressgen BioReagents was formed in...
...in April by Ampersand Ventures, at which time the company purchased the reagents business of Stressgen Biotechnologies Corp....
...C$8 million (US$6.5 million) (see BioCentury, April 18). Assay Designs Inc. , Ann Arbor, Mich. Stressgen...
BioCentury | Jul 4, 2005
Finance

Restructuring watch

...multiple Phase I and II pain and cancer compounds and a gene expression technology. 4/27/05 Stressgen...
BioCentury | May 9, 2005
Company News

Stressgen, Ampersand Ventures deal

...BioCentury, April 18). Stressgen BioReagents was formed by Ampersand. The sale included 26 SSB employees. Stressgen Biotechnologies Corp....
Items per page:
1 - 10 of 134